See more : CH Biotech R&D Co., Ltd. (6534.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Paion AG (0NF3.L) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Paion AG, a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Angel Fibers Limited (ANGEL.BO) Income Statement Analysis – Financial Results
- Sitios Latinoamérica, S.A.B. de C.V. (SLAAF) Income Statement Analysis – Financial Results
- K & P International Holdings Limited (0675.HK) Income Statement Analysis – Financial Results
- ROBOTIS Co., Ltd. (108490.KQ) Income Statement Analysis – Financial Results
- Enbridge Inc. CUM RED PFD 19 (ENB-PFK.TO) Income Statement Analysis – Financial Results
Paion AG (0NF3.L)
About Paion AG
Paion AG, a specialty pharmaceutical company, develops and commercializes drugs for hospital-based sedation, anesthesia, and critical care services worldwide. The company's lead product is Remimazolam, an ultra-short-acting intravenous benzodiazepine sedative/anesthetic, which is in clinical development for use in procedural sedation, general anesthesia, and intensive care unit sedation. It is also developing Angiotensin II, a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock; and Eravacycline, a novel fluorocycline antibiotic indicated for the treatment of complicated intra-abdominal infections in adults. The company has partnerships and license agreements with Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Paion AG was founded in 2000 and is based in Aachen, Germany.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.25M | 7.13M | 19.66M | 8.00M | 2.77M | 5.81M | 4.26M | 71.61K | 3.46M | 4.23M | 26.81M | 3.25M | 4.47M | 1.53M | 3.17M | 0.00 | 0.00 | 18.80M | 16.95M | 708.72K |
| Cost of Revenue | 1.96M | 3.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.94K | 4.15K | 0.00 | 1.30K | 1.71K | 19.49K | 50.90K | 780.45K | -2.98M | -7.25M | 4.85M | 2.44M | 425.76K |
| Gross Profit | 31.29M | 4.05M | 19.66M | 8.00M | 2.77M | 5.81M | 4.26M | 60.67K | 3.45M | 4.23M | 26.81M | 3.25M | 4.45M | 1.48M | 2.39M | 2.98M | 7.25M | 13.94M | 14.51M | 282.96K |
| Gross Profit Ratio | 94.10% | 56.83% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 84.72% | 99.88% | 100.00% | 100.00% | 99.95% | 99.56% | 96.68% | 75.35% | 0.00% | 0.00% | 74.17% | 85.61% | 39.93% |
| Research & Development | 6.49M | 5.25M | 10.29M | 13.10M | 12.17M | 17.85M | 23.41M | 29.38M | 11.80M | 4.58M | 3.25M | 11.82M | 9.02M | 10.59M | 8.73M | -9.81M | -16.49M | 13.63M | 7.98M | 8.81M |
| General & Administrative | 21.20M | 19.83M | 7.52M | 5.02M | 3.41M | 3.83M | 5.13M | 5.73M | 3.70M | 3.31M | 4.71M | 4.81M | 4.54M | 4.35M | 7.55M | 0.00 | 0.00 | 4.85M | 5.71M | 2.43M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 86.28K | -559.57K | -1.09M | 1.37M | 647.12K | 49.04K |
| SG&A | 21.20M | 19.83M | 7.52M | 5.02M | 3.41M | 3.83M | 5.13M | 5.73M | 3.70M | 3.31M | 4.71M | 4.81M | 4.54M | 4.35M | 7.63M | -559.57K | -1.09M | 6.22M | 6.36M | 2.48M |
| Other Expenses | 2.10M | 989.00K | -260.80K | 796.27K | 353.80K | -2.36K | -806.89K | 965.09K | 410.69K | 860.15K | 16.36K | -29.46K | -68.44K | -456.18K | -176.70K | 0.00 | 0.00 | -93.91K | 268.80K | -84.22K |
| Operating Expenses | 29.78M | 26.07M | 17.81M | 18.12M | 15.57M | 21.68M | 28.54M | 35.11M | 15.50M | 7.90M | 7.96M | 16.61M | 13.49M | 14.48M | 16.19M | -10.37M | -17.57M | 19.76M | 14.60M | 11.21M |
| Cost & Expenses | 31.74M | 29.14M | 17.81M | 18.12M | 15.57M | 21.68M | 28.54M | 35.12M | 15.51M | 7.90M | 7.96M | 16.61M | 13.51M | 14.53M | 16.97M | -13.35M | -24.83M | 24.61M | 17.04M | 11.63M |
| Interest Income | 1.10M | 1.56M | 10.61K | 975.69 | 6.00K | 20.00K | 21.00K | 42.00K | 66.00K | 55.00K | 82.79K | 106.78K | 76.54K | 354.60K | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.80M | 2.07M | 162.92K | 123.39K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 42.00K | 767.00K | 737.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.71M | 3.19M | 353.52K | 915.40K | 255.57K | 347.25K | 758.91K | 124.82K | 92.69K | 389.63K | 246.20K | 6.63M | 888.81K | 167.79K | 880.64K | 522.44K | 364.24K | 410.68K | 354.07K | 882.33K |
| EBITDA | 4.31M | -18.82M | 1.94M | -9.21M | -12.55M | -15.52M | -23.52M | -34.93M | -11.48M | -2.59M | 18.56M | -6.62M | -8.07M | -12.83M | -12.92M | 13.87M | 25.19M | -5.40M | 266.97K | -10.04M |
| EBITDA Ratio | 12.96% | -264.08% | 9.85% | -115.08% | -453.87% | -267.12% | -551.80% | -48,772.49% | -332.20% | -61.20% | 69.23% | -203.89% | -180.30% | -836.63% | -408.00% | 0.00% | 0.00% | -28.75% | 1.57% | -1,417.15% |
| Operating Income | 2.60M | -22.01M | 1.58M | -10.12M | -12.46M | -15.87M | -25.08M | -34.09M | -11.64M | -2.81M | 18.87M | -13.36M | -9.03M | -13.00M | -13.80M | -12.62M | 24.83M | -5.81M | -87.11K | -10.93M |
| Operating Income Ratio | 7.83% | -308.84% | 8.05% | -126.53% | -450.31% | -273.13% | -588.54% | -47,599.17% | -336.79% | -66.46% | 70.37% | -411.28% | -201.88% | -847.58% | -435.81% | 0.00% | 0.00% | -30.94% | -0.51% | -1,541.65% |
| Total Other Income/Expenses | -1.71M | -503.00K | -205.32K | 673.86K | 6.18K | 19.81K | -1.04M | 948.69K | 471.80K | 183.62K | -592.35K | -660.22K | -660.49K | -381.38K | 812.81K | 0.00 | 0.00 | 1.06M | 263.19K | 61.53K |
| Income Before Tax | -201.00K | -22.58M | 1.43M | -9.45M | -12.45M | -15.85M | -25.06M | -34.05M | -11.57M | -2.98M | 18.28M | -14.02M | -9.69M | -13.38M | -12.99M | 0.00 | 0.00 | -4.76M | 176.08K | -10.86M |
| Income Before Tax Ratio | -0.60% | -316.78% | 7.28% | -118.10% | -450.09% | -272.79% | -588.05% | -47,540.95% | -334.89% | -70.49% | 68.16% | -431.60% | -216.64% | -872.45% | -410.14% | 0.00% | 0.00% | -25.30% | 1.04% | -1,532.97% |
| Income Tax Expense | 378.00K | -795.89K | -791.66K | -2.43M | -2.51M | -3.76M | -4.94M | -5.83M | -2.47M | -768.13K | 2.27M | -339.16K | -439.22K | -339.57K | -406.01K | 23.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -579.00K | -21.79M | 2.22M | -7.02M | -9.94M | -12.09M | -20.12M | -28.21M | -9.10M | -2.21M | 16.01M | -13.68M | -9.25M | -13.04M | -12.58M | -10.51M | 0.00 | -4.76M | 176.08K | -10.86M |
| Net Income Ratio | -1.74% | -305.62% | 11.31% | -87.70% | -359.36% | -208.11% | -472.05% | -39,394.65% | -263.46% | -52.32% | 59.71% | -421.16% | -206.82% | -850.30% | -397.32% | 0.00% | 0.00% | -25.30% | 1.04% | -1,532.97% |
| EPS | -0.08 | -3.11 | 0.30 | -1.06 | -1.56 | -2.01 | -3.71 | -5.43 | -2.22 | -0.71 | 5.10 | -4.38 | -3.04 | -4.29 | -4.88 | -5.08 | 0.00 | -2.54 | 0.16 | -11.20 |
| EPS Diluted | -0.08 | -3.11 | 0.30 | -1.06 | -1.56 | -1.99 | -3.70 | -5.40 | -2.20 | -0.71 | 5.10 | -4.36 | -3.00 | -4.28 | -4.88 | -5.08 | 0.00 | -2.54 | 0.16 | -9.24 |
| Weighted Avg Shares Out | 7.13M | 6.99M | 6.57M | 6.62M | 6.36M | 6.02M | 5.42M | 5.20M | 4.09M | 3.14M | 3.14M | 3.13M | 3.05M | 3.04M | 2.58M | 2.07M | 2.07M | 1.87M | 1.18M | 970.09K |
| Weighted Avg Shares Out (Dil) | 7.13M | 7.02M | 6.61M | 6.63M | 6.39M | 6.06M | 5.44M | 5.22M | 4.14M | 3.14M | 3.14M | 3.14M | 3.08M | 3.04M | 2.58M | 2.07M | 2.07M | 1.87M | 1.18M | 1.18M |
Source: https://incomestatements.info
Category: Stock Reports